HC Wainwright Issues Optimistic Estimate for CANF Earnings

Can-Fite BioPharma Ltd. (NYSE:CANF) – Stock analysts at HC Wainwright increased their Q3 2024 earnings per share estimates for shares of Can-Fite BioPharma in a research note issued on Tuesday, November 12th. HC Wainwright analyst V. Bernardino now forecasts that the company will earn ($0.27) per share for the quarter, up from their previous estimate of ($0.29). HC Wainwright has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for Can-Fite BioPharma’s current full-year earnings is ($1.29) per share. HC Wainwright also issued estimates for Can-Fite BioPharma’s Q4 2024 earnings at ($0.24) EPS, FY2024 earnings at ($1.25) EPS and FY2025 earnings at ($0.05) EPS.

A number of other equities analysts have also weighed in on CANF. EF Hutton Acquisition Co. I upgraded shares of Can-Fite BioPharma to a “strong-buy” rating in a research report on Wednesday, July 17th. StockNews.com upgraded Can-Fite BioPharma from a “sell” rating to a “hold” rating in a research report on Tuesday.

Can-Fite BioPharma Stock Down 0.5 %

Can-Fite BioPharma stock opened at $2.07 on Thursday. Can-Fite BioPharma has a 52-week low of $1.83 and a 52-week high of $4.69. The company has a market cap of $7.33 million, a P/E ratio of -1.16 and a beta of 1.39. The business has a 50-day simple moving average of $2.26 and a two-hundred day simple moving average of $2.52.

Hedge Funds Weigh In On Can-Fite BioPharma

An institutional investor recently raised its position in Can-Fite BioPharma stock. Armistice Capital LLC lifted its holdings in Can-Fite BioPharma Ltd. (NYSE:CANF) by 35.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 518,853 shares of the company’s stock after acquiring an additional 136,055 shares during the period. Armistice Capital LLC owned 14.66% of Can-Fite BioPharma worth $1,339,000 at the end of the most recent quarter. Institutional investors and hedge funds own 21.00% of the company’s stock.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.